explore -WSS

explore

author：focus 2025-09-30 20:20:27 - browse：156

JOSEPH PREZIOSO/AFP via Getty Images

LONDON — The U.K.’s cost-effectiveness watchdog said Thursday it is not yet recommending Vertex’s CRISPR-based therapy for sickle cell disease, saying in draft guidance it has questions about the medicine’s lasting benefits for patients.

U.K. regulators approved the therapy, known as Casgevy or exa-cel, last year, granting it the world’s first authorization for any CRISPR-based medicine. But observers have been watching to see how the U.K.’s National Institute for Health and Care Excellence, as well as similar agencies in European countries, would view the pricey, one-time therapy. NICE needs to recommend the therapy for it to be offered in the National Health Service.

In the U.S., Casgevy has a list price of $2.2 million. It was developed by Vertex in partnership with CRISPR Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： BD to buy Edwards patient monitoring unit for $4.2 billion

WSS

US judge blocks portions of new Florida elections law

UnitedHealth CEO's Medicaid comments send insurer stocks diving

Noem? Reynolds? A very early look at the Republican 'veepstakes'

Masked assailants attack a journalist and a lawyer in Russia's Chechnya province

Elevance PBM president out as customers face prescription chaos

For pregnant people, addiction treatment shouldn't mean a call to child protective services

focus

explore

entertainment

Medical records are filled with copy

FDA approves Moderna’s RSV vaccine, its second licensed product

Wildfire smoke exposes gaps in outdoor worker protections

Structure Therapeutics oral GLP

Medical leaders decry Supreme Court decision on affirmative action

Finland to offer bird flu vaccine to select groups of people, a possible global first

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Eli Lilly’s Zepbound improved liver scarring in mid

After affirmative action ruling, medical educators look to 'holistic review'

Leon Gautier, last member of French D

hotspot

Finland to offer bird flu vaccine to select groups of people, a possible global first

Churchill Downs extends trainer Bob Baffert's ban through 2024

Churchill Downs extends trainer Bob Baffert's ban through 2024

US ambassador visits Wall Street Journal reporter detained in Russia on charges of espionage

Russians and Belarusians back at Wimbledon as war in Ukraine continues

ASCO Daily Recap: CAR

explore

focus

knowledge

focus